A committee selected by RFK Jr. has approved the manufacture of peptides that he reportedly uses himself, according to the Ars Technica report. The central controversy is that the move appears to have gone forward without human data showing the products are safe or effective.
That lack of evidence is the key issue in the story. In most health-related decisions, human safety and efficacy findings are a basic benchmark for judging whether a product should move ahead. Here, the report suggests those standards no longer carried the same weight in the approval process.
The decision is likely to intensify debate over how evidence is being used in public health and regulatory discussions. Critics are expected to focus on the combination of personal interest, a hand-picked committee, and the absence of human trial data supporting the peptides in question.
More broadly, the episode highlights a larger concern about whether long-standing scientific safeguards are being weakened. When products advance without clear human evidence, questions quickly follow about oversight, transparency, and the standards being applied.
